Advertisement

Topics

Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And ...

16:15 EST 13 Nov 2017 | BioMedReports - Blog

"We are very encouraged by the early results from our sitravatinib immuno-oncology program. The combination of sitravatinib and nivolumab has demonstrated durable responses and prolonged

Read more...

Original Article: Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And ...

NEXT ARTICLE

More From BioPortfolio on "Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...